In a welcome move, Neurocrine Biosciences saw its Relative Strength Rating rise from 64 to 75 on Thursday.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique rating tracks price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research shows that the best-performing stocks often have an RS Rating of above 80 in the early stages of their moves. See if Neurocrine Biosciences can continue to rebound and hit that benchmark.
Neurocrine Biosciences has risen more than 5% past a 130.46 entry in a first-stage cup with handle, meaning it's now out of a proper buy zone. Look for the stock to create a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Top and bottom line growth moved higher in the company's most recent quarter. Earnings were up 1%, compared to -42% in the prior report. Revenue increased from 11% to 16%.
The company earns the No. 25 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Rigel Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
